Key result
Staged Micra and MitraClip strategy successfully reduces lead-associated severe tricuspid regurgitation to moderate.
Why the study?
Pacemaker lead-associated severe tricuspid regurgitation can cause right heart failure and poor prognosis, and surgery carries significant morbidities in these patients.
Does a staged transcatheter approach with leadless pacemaker implantation and MitraClip repair improve lead-associated severe tricuspid regurgitation in a high-risk surgical patient?
Case Report (n=1)
Does a staged transcatheter approach with leadless pacemaker implantation and MitraClip repair improve lead-associated severe tricuspid regurgitation in a high-risk surgical patient?
A staged transcatheter strategy involving lead extraction, leadless pacemaker implantation, and edge-to-edge repair can successfully treat pacemaker lead-associated severe tricuspid regurgitation in patients at extreme surgical risk.
No takes yet. Share an insight, caveat, or question.
May offer transcatheter option for lead-associated TR; hypothesis-generating and requires prospective validation before practice change.
Tang et al. (2017) conducted a case report in Lead-associated severe tricuspid regurgitation and moderate-severe mitral regurgitation (n=1). Leadless pacemaker implantation and tricuspid valve repair with MitraClip NT was evaluated on Procedural success and reduction in regurgitation severity. A staged transcatheter strategy using a Micra leadless pacemaker and MitraClip NT successfully treated lead-associated severe tricuspid regurgitation, improving it to moderate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: